346 related articles for article (PubMed ID: 21542416)
1. Caco-2 cells, biopharmaceutics classification system (BCS) and biowaiver.
Smetanová L; Stĕtinová V; Svoboda Z; Kvetina J
Acta Medica (Hradec Kralove); 2011; 54(1):3-8. PubMed ID: 21542416
[TBL] [Abstract][Full Text] [Related]
2. Caco-2 cells and Biopharmaceutics Classification System (BCS) for prediction of transepithelial transport of xenobiotics (model drug: caffeine).
Smetanova L; Stetinova V; Kholova D; Kvetina J; Smetana J; Svoboda Z
Neuro Endocrinol Lett; 2009; 30 Suppl 1():101-5. PubMed ID: 20027153
[TBL] [Abstract][Full Text] [Related]
3. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs.
Dahan A; Amidon GL
Mol Pharm; 2009; 6(1):19-28. PubMed ID: 19248230
[TBL] [Abstract][Full Text] [Related]
4. Intestinal permeability study of minoxidil: assessment of minoxidil as a high permeability reference drug for biopharmaceutics classification.
Ozawa M; Tsume Y; Zur M; Dahan A; Amidon GL
Mol Pharm; 2015 Jan; 12(1):204-11. PubMed ID: 25423288
[TBL] [Abstract][Full Text] [Related]
5. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
6. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
[TBL] [Abstract][Full Text] [Related]
7. Demonstrating suitability of the Caco-2 cell model for BCS-based biowaiver according to the recent FDA and ICH harmonised guidelines.
Jarc T; Novak M; Hevir N; Rižner TL; Kreft ME; Kristan K
J Pharm Pharmacol; 2019 Aug; 71(8):1231-1242. PubMed ID: 31155721
[TBL] [Abstract][Full Text] [Related]
8. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests.
Kim JS; Mitchell S; Kijek P; Tsume Y; Hilfinger J; Amidon GL
Mol Pharm; 2006; 3(6):686-94. PubMed ID: 17140256
[TBL] [Abstract][Full Text] [Related]
9. Biowaiver: an alternative to in vivo pharmacokinetic bioequivalence studies.
Mishra V; Gupta U; Jain NK
Pharmazie; 2010 Mar; 65(3):155-61. PubMed ID: 20383933
[TBL] [Abstract][Full Text] [Related]
10. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
11. Regional intestinal drug permeation: biopharmaceutics and drug development.
Lennernäs H
Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
[TBL] [Abstract][Full Text] [Related]
12. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
13. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
[TBL] [Abstract][Full Text] [Related]
14. Do the recommended standards for in vitro biopharmaceutic classification of drug permeability meet the "passive transport" criterion for biowaivers?
Žakelj S; Berginc K; Roškar R; Kraljič B; Kristl A
Curr Drug Metab; 2013 Jan; 14(1):21-7. PubMed ID: 22497571
[TBL] [Abstract][Full Text] [Related]
15. Solubility Determination of Active Pharmaceutical Ingredients Which Have Been Recently Added to the List of Essential Medicines in the Context of the Biopharmaceutics Classification System-Biowaiver.
Plöger GF; Hofsäss MA; Dressman JB
J Pharm Sci; 2018 Jun; 107(6):1478-1488. PubMed ID: 29421214
[TBL] [Abstract][Full Text] [Related]
16. A new topological descriptors based model for predicting intestinal epithelial transport of drugs in Caco-2 cell culture.
Marrero Ponce Y; Cabrera Pérez MA; Romero Zaldivar V; González Díaz H; Torrens F
J Pharm Pharm Sci; 2004 Jun; 7(2):186-99. PubMed ID: 15367375
[TBL] [Abstract][Full Text] [Related]
17. The developability classification system: application of biopharmaceutics concepts to formulation development.
Butler JM; Dressman JB
J Pharm Sci; 2010 Dec; 99(12):4940-54. PubMed ID: 20821390
[TBL] [Abstract][Full Text] [Related]
18. Very rapid dissolution is not needed to guarantee bioequivalence for biopharmaceutics classification system (BCS) I drugs.
Kortejärvi H; Shawahna R; Koski A; Malkki J; Ojala K; Yliperttula M
J Pharm Sci; 2010 Feb; 99(2):621-5. PubMed ID: 19844950
[TBL] [Abstract][Full Text] [Related]
19. A Sensitive Medium-Throughput Method to Predict Intestinal Absorption in Humans Using Rat Intestinal Tissue Segments.
Da Silva LC; Da Silva TL; Antunes AH; Rezende KR
J Pharm Sci; 2015 Sep; 104(9):2807-12. PubMed ID: 25690454
[TBL] [Abstract][Full Text] [Related]
20. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
Lindenberg M; Kopp S; Dressman JB
Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
